Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 Vaccines Against Hospitalisations Among Children and Adolescents During the Omicron Outbreak in Argentina

González, Soledad; Olszevicki, Santiago; Gaiano, Alejandra; Varela, Ana Nina; Regairaz, Lorena; Salazar, Martín R.; Pesci, Santiago; Marín, Lupe; González, Verónica; Varela, Teresa; Ceriani, Leticia; García, Enio; Kreplak, Nicolás; Navarro, Alexia; Bakker, Jan; Mársico, Franco

doi:10.2139/ssrn.4087375

Cited by 6 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, we included 2 RCTs and 15 observational studies, including 12 cohort studies and 3 case-control studies (Figure 1). [12][13][14][15]19,20,[31][32][33][34][35][36][37][38][39][40][41][42] Baseline characteristics are summarized in Table 1 and eTable 1 in Supplement 1. There were 10 935 541 vaccinated children (mean or median age range, 8.0-9.5 years; 46.0%-55.9% female individuals) and 2 635 251 unvaccinated children (mean or median age range, 7.0-9.5 years; 44.3%-51.7% female individuals).…”

Section: Resultsmentioning

confidence: 99%

Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years

et al. 2023

View full text Add to dashboard Cite

ImportanceEvidence of the efficacy and safety of messenger RNA (mRNA) COVID-19 vaccines in children aged 5 to 11 years has been emerging. Collecting these data will inform clinicians, families, and policy makers.ObjectiveTo evaluate the efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years in a systematic review and meta-analysis.Data SourcesPubMed and Embase databases were searched on September 29, 2022, without language restrictions.Study SelectionRandomized clinical trials and observational studies comparing vaccinated vs unvaccinated children aged 5 to 11 years and reporting efficacy or safety outcomes were included. Studies reporting safety outcomes in vaccinated children only (ie, no control group) were also included.Data Extraction and SynthesisTwo investigators independently extracted relevant data from each study. Odds ratios (ORs) for efficacy and safety outcomes and incidences of adverse events (AEs) following vaccination were synthesized using a random-effects model. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology reporting guidelines.Main Outcomes and MeasuresThe primary outcome was SARS-CoV-2 infections with or without symptoms. The secondary outcomes included symptomatic SARS-CoV-2 infections, hospitalizations, and multisystem inflammatory syndrome in children. The incidences of each AE following vaccination were also evaluated.ResultsTwo randomized clinical trials and 15 observational studies involving 10 935 541 vaccinated children (median or mean age range, 8.0-9.5 years) and 2 635 251 unvaccinated children (median or mean age range, 7.0-9.5 years) were included. Two-dose mRNA COVID-19 vaccination compared with no vaccination was associated with lower risks of SARS-CoV-2 infections with or without symptoms (OR, 0.47; 95% CI, 0.35-0.64), symptomatic SARS-CoV-2 infections (OR, 0.53; 95% CI, 0.41-0.70), hospitalizations (OR, 0.32; 95% CI, 0.15-0.68), and multisystem inflammatory syndrome in children (OR, 0.05; 95% CI, 0.02-0.10). Two randomized clinical trials and 5 observational studies investigated AEs among vaccinated children. Most vaccinated children experienced at least 1 local AE following the first injection (32 494 of 55 959 [86.3%]) and second injection (28 135 of 46 447 [86.3%]). Vaccination was associated with a higher risk of any AEs compared with placebo (OR, 1.92; 95% CI, 1.26-2.91). The incidence of AEs that prevented normal daily activities was 8.8% (95% CI, 5.4%-14.2%) and that of myocarditis was estimated to be 1.8 per million (95% CI, 0.000%-0.001%) following the second injection.Conclusions and RelevanceIn this systematic review and meta-analysis, COVID-19 mRNA vaccines among children aged 5 to 11 years were associated with measures of efficacy in preventing SARS-CoV-2 infection and severe COVID-19–related illnesses. While most children developed local AEs, severe AEs were rare, and most of AEs resolved within several days. These data provide evidence for future recommendations.

show abstract

Section: Resultsmentioning

confidence: 99%

Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The NOS scores indicated that all the studies included in the analysis demonstrated moderate to high methodological quality. Among them, 17 studies ( 10 , 17–19 , 23–26 , 28 , 29 , 32 , 34 , 35 , 38 , 43 , 45 ) were rated as high quality, while 16 studies ( 11 , 12 , 20–22 , 27 , 30 , 31 , 33 , 36 , 37 , 39–42 , 44 ) were considered to be of medium quality ( Supplementary Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis

Lu,

Zeng,

Yao

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundOmicron (B.1.1.529), a variant of SARS-CoV-2, has emerged as a dominant strain in COVID-19 pandemic. This development has raised concerns about the effectiveness of vaccination to Omicron, particularly in the context of children and adolescents. Our study evaluated the efficacy of different COVID-19 vaccination regimens in children and adolescents during the Omicron epidemic phase.MethodsWe searched PubMed, Cochrane, Web of Science, and Embase electronic databases for studies published through March 2023 on the association between COVID-19 vaccination and vaccine effectiveness (VE) against SARS-CoV-2 infection in children and adolescents at the Omicron variant period. The effectiveness outcomes included mild COVID-19 and severe COVID-19. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was prospectively registered in PROSPERO (CRD42023390481).ResultsA total of 33 studies involving 16,532,536 children were included in the analysis. First, in children and adolescents aged 0–19 years, the overall VE of the COVID-19 vaccine is 45% (95% confidence interval [CI]: 40 to 50%). Subgroup analysis of VE during Omicron epidemic phase for different dosage regimens demonstrated that the VE was 50% (95% CI: 44 to 55%) for the 2-dose vaccination and 61% (95% CI: 45 to 73%) for the booster vaccination. Upon further analysis of different effectiveness outcomes during the 2-dose vaccination showed that the VE was 41% (95% CI: 35 to 47%) against mild COVID-19 and 71% (95% CI: 60 to 79%) against severe COVID-19. In addition, VE exhibited a gradual decrease over time, with the significant decline in the efficacy of Omicron for infection before and after 90 days following the 2-dose vaccination, registering 54% (95% CI: 48 to 59%) and 34% (95% CI: 21 to 56%), respectively.ConclusionDuring the Omicron variant epidemic, the vaccine provided protection against SARS-CoV-2 infection in children and adolescents aged 0–19 years. Two doses of vaccination can provide effective protection severe COVID-19, with booster vaccination additionally enhancing VE.

show abstract

“…Both antibody binding and neutralizing antibody responses to SARS-CoV-2 in both very young children and adolescents exceeded those in adults [ 84 , 85 ]. Besides these two mRNA-based vaccines, Sinovac-CoronaVac and BBIBP-CorV, which are based on the inactivated virus, were approved in China for children aged 3–17 years [ 86 , 87 ]. Similarly, Covaxin (BB152), which is also based on an inactivated virus strategy and developed by Bharat Biotech, India, was approved in India under the EUA category [ 88 , 89 ].…”

Section: Status Of Vaccination In Childrenmentioning

confidence: 99%

Children’s SARS-CoV-2 Infection and Their Vaccination

et al. 2023

View full text Add to dashboard Cite

SARS-CoV-2, a novel coronavirus, causes respiratory tract infections and other complications in affected individuals, and has resulted in numerous deaths worldwide. The unprecedented pace of its transmission worldwide, and the resultant heavy burden on healthcare systems everywhere, prompted efforts to have effective therapeutic strategies and vaccination candidates available to the global population. While aged and immunocompromised individuals form a high-risk group for COVID-19 and have severe disease outcome, the rate of infections among children has also increased with the emergence of the Omicron variant. In addition, recent reports of threatening SARS-CoV-2-associated complications in children have brought to the forefront an urgent necessity for vaccination. In this article, we discuss the current scenario of SARS-CoV-2 infections in children with a special focus on the differences in their immune system response as compared to adults. Further, we describe the various available COVID-19 vaccines, including the recent bivalent vaccines for children, in detail, intending to increase willingness for their acceptance.

show abstract

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 Vaccines Against Hospitalisations Among Children and Adolescents During the Omicron Outbreak in Argentina

Cited by 6 publications

References 13 publications

Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years

Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years

The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis

Children’s SARS-CoV-2 Infection and Their Vaccination

Contact Info

Product

Resources

About